BIMOLET
BRIMONIDIN TARTRATE USP+ TIMOLOL MELATE BP
| NAME | STRENGTH | PACK SIZE | DOSAGE FORM |
|---|---|---|---|
| BIMOLET 0.2% W/V + 0.5% W/V | 0.2% W/V + 0.5% W/V | 5 ML | EYE DROP |
Bimolet Eye Drops : Each ml contains Brimonidine Tartrate INN 2 mg and Timolol Maleate BP equivalent to Timolol 5 mg
Brimonidine is more selective for the alpha-2 adrenoreceptor. It is thought that Brimonidine Tartrate lowers IOP by enhancing uveoscleral outflow and reducing aqueous humour formation. Timolol is a beta 1 and beta 2 non-selective adrenergic receptor blocking agent. Timolol lowers IOP by reducing aqueous humour formation. The precise mechanism of action is not clearly established, predominant action may be related to reduce aqueous formation. However, in some studies a slight increase in outflow facility was also observed.
Bimolet is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.
The recommended dose is one drop of this eye drops in the affected eye(s) twice daily approximately 12 hours apart.
Contraindicated in patients with hypersensitivity to any component of this product. Also contraindicated in bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure and cardiogenic shock.
Like other topically applied ophthalmic agents, it may be absorbed systemically. Due to the presence of Timolol, the same types of cardiovascular and pulmonary adverse reactions as seen with systemic beta-blockers may occur. Cautions should be exercised in treating patients with severe or unstable and uncontrolled cardiovascular or pulmonary diseases.
The most frequent reactions of this combination are allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, ocular burning, blepharitis, corneal erosion, epiphora, eye dryness, eye pain, eyelid edema, eyelid pruritus, headache, hypertension, superficial punctate keratitis, and visual disturbance.
Pregnancy: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Bimolet should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: Timolol has been detected in human milk but it is not known whether Brimonidine Tartrate is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Specific drug interaction studies on this ophthalmic preparation have not been established.
No information is available on overdoses with this drop in humans.
Store in a cool & dry place, protected from light. Keep out of reach of children. Do not use more than 30 days after first opening.
Bimolet Eye Drops : Each plastic dropper bottle contains 5 ml sterile eye drops.